Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Active Not Recruiting NCT05181618

A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis

Conditions: Severe Hemophilia A, Moderate Hemophilia A

Sex: All

Ages: 13 Years – 69 Years

Healthy volunteers: No

Phase: PHASE4

Enrollment: 136

Sponsor: Hoffmann-La Roche

Location: Orthopaedic Institute for Children Los Angeles California

Summary

Study MO42623 is a Phase IV, multicenter, open-label, three cohort study designed to evaluate the impact of emicizumab prophylaxis on overall health, physical activity, and joint outcomes in participants aged ≥13 and \

Eligibility Criteria

Inclusion Criteria: * Diagnosis of severe congenital hemophilia A (intrinsic factor VIII \[FVIII\] level \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05181618). StuddyBuddy aggregates publicly available trial information.